Effect of Intermittent Cyclical Etidronate Therapy on Corticosteroid Induced Osteoporosis in Japanese Patients with Connective Tissue Disease: 3 Year Followup

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2673-2679

  Sato, Shinji ^a,d   Ohosone, Yasuo ^b   Suwa, Akira ^a   Yasuoka, Hidekata ^a   Nojima, Takaki ^a   Fujii, Takao ^c   Kuwana, Masataka ^a   Nakamura, Kunio ^a   Mimori, Tsuneyo ^c   Hirakata, Michito ^a  

^a KEIO UNIVERSITY   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Bone mineral density; Connective tissue diseases; Corticosteroid induced osteoporosis

Indexed keywords

ALFACALCIDOL; CALCIUM LACTATE; CORTICOSTEROID; ETIDRONIC ACID; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; JAPAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADULT; BONE DENSITY; CALCIUM COMPOUNDS; CONNECTIVE TISSUE DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; LACTATES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 10744232135     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
2. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
3. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
4. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
5. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
6. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
7. Pitt P, Li F, Todd P, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998;53:351-6.
8. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81.
9. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
10. Sebaldt RJ, Ioannidis G, Adachi ID, et al. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 1999;26:1545-9.
11. Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999;26:1148-57.
12. 2 (menatetrenone) effectively prevents fractures and susta ns lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-21.
13. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
14. Dougherty JA. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. Ann Pharmacother 2002;36:512-6.
15. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-7.
16. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp 2002;63:606-20.
17. Orimo H, Sugioka Y, Fukunaga H, et al. Diagnostic criteria for primary osteoporosis recommended by the Japanese Society of Bone and Mineral Research in 1996. Osteoporosis Japan 1996;4:65-75.
18. Alexandre C, Meunier PJ, Edouard C, Khairi RA, Johnston CC. Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. Metab Bone Dis Relat Res 1981;3:309-15.
19. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
20. Fujita T, Orimo H, Inoue T, et al. Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 1993;21:261-302.
21. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103:468-76.
22. Orimo H, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner 1987;3:47-52.
23. Masud T, Mulcahy B, Thompson AV, et al. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 1998;57:346-9.
24. Shiraki M, Kushida K, Yamazaki K, et al. Effects of 2 years treatment of osteoporosis with 1-alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture-a placebo-controlled, double-blind prospective study. Endocrine J 1996;43:211-20.
25. Chen JT, Shiraki M, Hasumi K, et al. 1-alpha-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997;20:557-62.
26. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999;10:183-92.
27. Lakatos P, Nagy Z, Kiss L, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000;59 Suppl 1:48-52.